2024-01-29 14:17:45 ET
Summary
- Corbus Pharmaceuticals has experienced a surge in stock price after positive clinical results for their antibody drug conjugate, CRB-701.
- CRBP is conducting phase 1 studies for CRB-701 in patients with Nectin-4-positive solid tumors, showing favorable tolerability and promising efficacy.
- The company's financial situation is concerning, with limited cash on hand and the need for significant financing to continue operations.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds